HAS-UD Vascular Biology and Myocardial Pathophysiology Research Group, Hungarian Academy of Sciences, Debrecen, Hungary.
Department of Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Br J Pharmacol. 2020 Feb;177(4):793-809. doi: 10.1111/bph.14691. Epub 2019 Apr 24.
Calcification of heart valves is a frequent pathological finding in chronic kidney disease and in elderly patients. Hydrogen sulfide (H S) may exert anti-calcific actions. Here we investigated H S as an inhibitor of valvular calcification and to identify its targets in the pathogenesis.
Effects of H S on osteoblastic transdifferentiation of valvular interstitial cells (VIC) isolated from samples of human aortic valves were studied using immunohistochemistry and western blots. We also assessed H2S on valvular calcification in apolipoprotein E-deficient (ApoE ) mice.
In human VIC, H S from donor compounds (NaSH, Na S, GYY4137, AP67, and AP72) inhibited mineralization/osteoblastic transdifferentiation, dose-dependently in response to phosphate. Accumulation of calcium in the extracellular matrix and expression of osteocalcin and alkaline phosphatase was also inhibited. RUNX2 was not translocated to the nucleus and phosphate uptake was decreased. Pyrophosphate generation was increased via up-regulating ENPP2 and ANK1. Lowering endogenous production of H S by concomitant silencing of cystathionine γ-lyase (CSE) and cystathionine β-synthase (CBS) favoured VIC calcification. analysis of human specimens revealed higher Expression of CSE in aorta stenosis valves with calcification (AS) was higher than in valves of aortic insufficiency (AI). In contrast, tissue H S generation was lower in AS valves compared to AI valves. Valvular calcification in ApoE mice on a high-fat diet was inhibited by H S.
The endogenous CSE-CBS/H S system exerts anti-calcification effects in heart valves providing a novel therapeutic approach to prevent hardening of valves.
This article is part of a themed section on Hydrogen Sulfide in Biology & Medicine. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.4/issuetoc.
心脏瓣膜钙化是慢性肾脏病和老年患者的常见病理发现。硫化氢(H2S)可能具有抗钙化作用。在这里,我们研究了 H2S 作为一种抑制瓣膜钙化的物质,并确定其在发病机制中的靶点。
使用免疫组织化学和蛋白质印迹法研究了 H2S 对从人主动脉瓣样本中分离的瓣膜间质细胞(VIC)成骨细胞分化的影响。我们还评估了 H2S 在载脂蛋白 E 缺陷(ApoE)小鼠中的瓣膜钙化作用。
在人 VIC 中,供体化合物(NaSH、Na2S、GYY4137、AP67 和 AP72)中的 H2S 抑制了矿物质/成骨细胞分化,对磷酸盐呈剂量依赖性。细胞外基质中钙的积累和骨钙素和碱性磷酸酶的表达也受到抑制。RUNX2 未向核内易位,磷酸盐摄取减少。通过上调 ENPP2 和 ANK1 增加焦磷酸盐的生成。同时沉默半胱氨酸γ-裂解酶(CSE)和半胱氨酸β-合酶(CBS)降低内源性 H2S 的产生有利于 VIC 钙化。对人标本的分析显示,伴有钙化的主动脉瓣狭窄(AS)中 CSE 的表达高于主动脉瓣关闭不全(AI)。相比之下,AS 瓣膜组织中的 H2S 生成量低于 AI 瓣膜。高脂饮食的 ApoE 小鼠的瓣膜钙化被 H2S 抑制。
内源性 CSE-CBS/H2S 系统在心脏瓣膜中发挥抗钙化作用,为预防瓣膜变硬提供了一种新的治疗方法。
本文是生物学与医学中硫化氢专题的一部分。要查看该部分的其他文章,请访问 http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.4/issuetoc。